Breaking News

Catalent, AveXis Enter Long-term Strategic Mfg. Pact

AveXis will have dedicated manufacturing space at Paragon’s new commercial manufacturing center near Baltimore-Washington Int’l Airport

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent Biologics entered a long-term strategic agreement for the development and manufacture of Zolgensma (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA). AveXis, a Novartis company, will have dedicated manufacturing space at the new commercial manufacturing center near Baltimore-Washington International Airport established by Paragon Gene Therapy, a unit of Catalent Biologics. This additional capacity, along with access to Catalent’s aden...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters